^
    6d
    A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection (clinicaltrials.gov)
    P2, N=100, Active, not recruiting, Vir Biotechnology, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Apr 2031 --> Jul 2030
    Enrollment closed • Trial completion date
    14d
    CD73 blockade enhances antitumor efficacy of oHSV in solid tumors by increasing macrophage-mediated antigen presentation. (PubMed, J Immunother Cancer)
    Here, we identify that immunosuppressive eADO signaling in the TME is a major barrier to oHSV therapy and CD73 blockade prevents tumor immune escape. The combination of oHSV with CD73 blockade supports the development of an antitumor immune memory response in solid tumors. This study supports clinical development of this combination strategy.
    Journal • IO biomarker
    |
    CD73 (5'-Nucleotidase Ecto) • CD4 (CD4 Molecule) • NT5E (5'-Nucleotidase Ecto) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1) • ADORA2B (Adenosine A2b Receptor)
    |
    linoserpaturev (CAN-3110)
    23d
    All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, Dwight Owen | Trial primary completion date: Jan 2026 --> Sep 2025
    Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    Tecentriq (atezolizumab) • Vesanoid (tretinoin)
    1m
    Evaluation of ATRA Activity in Combination With Anastrozole in Pre-operative Phase of Operable Early Breast Cancer (clinicaltrials.gov)
    P2, N=76, Terminated, Mario Negri Institute for Pharmacological Research | N=112 --> 76 | Trial completion date: Sep 2024 --> Jan 2025 | Recruiting --> Terminated | Trial primary completion date: Aug 2024 --> Jan 2025; Low enrolment rate
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    anastrozole • Vesanoid (tretinoin)
    1m
    Oncolytic HSV-1-Mediated JAG1 Blockade Induces Glioma Senescence-Associated Secretory Phenotype to Increase Macrophage Activation and Cetuximab-Mediated Senolysis. (PubMed, Cancer Res)
    Clinically, the Notch ligand JAG1 was upregulated in recurrent high-grade glioma patients treated with the oHSV CAN-3110 and correlated with poor prognosis. Heightened EGFR activation in senescent cells was a mechanism to escape cell death, which created a unique opportunity for cetuximab as a senolytic agent. Combination therapy reduced EGFR signaling and induced macrophage-mediated antibody-dependent cellular cytotoxicity, thereby increasing the anti-tumor therapeutic efficacy of OD-0J1.
    Journal
    |
    HMGB1 (High Mobility Group Box 1) • CDK1 (Cyclin-dependent kinase 1) • IL1B (Interleukin 1, beta) • JAG1 (Jagged Canonical Notch Ligand 1)
    |
    Erbitux (cetuximab) • linoserpaturev (CAN-3110)
    1m
    Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia (clinicaltrials.gov)
    P2, N=151, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    RARA (Retinoic Acid Receptor Alpha) • PML (Promyelocytic Leukemia)
    |
    Mylotarg (gemtuzumab ozogamicin) • Vesanoid (tretinoin) • arsenic trioxide
    2ms
    Adoptive cell transfer therapy with ex vivo primed peripheral lymphocytes in combination with chemotherapy in locally advanced or metastatic triple-negative breast cancer: the ImmunoBreast phase Ib clinical trial. (PubMed, J Immunother Cancer)
    ALECSAT, in combination with carboplatin and gemcitabine, was safe, well tolerated, and demonstrated promising antitumor activity in mTNBC. These findings support further investigation in larger clinical trials.
    P1 data • Preclinical • Journal
    |
    CD8 (cluster of differentiation 8)
    |
    carboplatin • gemcitabine • Alecsat (cytotoxic lymphocyte-based cancer vaccine)
    2ms
    Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis (clinicaltrials.gov)
    P1, N=23, Terminated, Xencor, Inc. | N=128 --> 23 | Active, not recruiting --> Terminated; Business Decision
    Enrollment change • Trial termination
    2ms
    A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection (clinicaltrials.gov)
    P1/2, N=33, Completed, Vir Biotechnology, Inc. | Active, not recruiting --> Completed | N=150 --> 33 | Trial completion date: Mar 2027 --> Aug 2025
    Trial completion • Enrollment change • Trial completion date
    2ms
    INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) (clinicaltrials.gov)
    P1/2, N=52, Active, not recruiting, Inovio Pharmaceuticals | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    temozolomide • Libtayo (cemiplimab-rwlc) • INO-5401 • rocakinogene sifuplasmid (INO-9012)
    2ms
    A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection (clinicaltrials.gov)
    P3, N=124, Active, not recruiting, Vir Biotechnology, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    2ms
    All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, Dwight Owen | Suspended --> Active, not recruiting | Trial completion date: Oct 2025 --> Jan 2026 | Trial primary completion date: Oct 2025 --> Jan 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    Tecentriq (atezolizumab) • Vesanoid (tretinoin)